Free Trial

Medtronic (MDT) Stock Forecast & Price Target

Medtronic logo
$97.88 -0.45 (-0.46%)
Closing price 03:59 PM Eastern
Extended Trading
$97.50 -0.38 (-0.39%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
8
Buy
13

Based on 22 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 1 has given a sell rating, 8 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for MDT.

Consensus Price Target

$101.63
3.83% Upside
According to the 22 analysts' twelve-month price targets for Medtronic, the average price target is $101.63. The highest price target for MDT is $115.00, while the lowest price target for MDT is $81.00. The average price target represents a forecasted upside of 3.83% from the current price of $97.88.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

TypeCurrent Forecast
10/8/24 to 10/8/25
1 Month Ago
9/8/24 to 9/8/25
3 Months Ago
7/10/24 to 7/10/25
1 Year Ago
10/9/23 to 10/8/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$101.63$102.14$97.47$94.64
Forecasted Upside3.83% Upside9.94% Upside9.04% Upside7.38% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyHold

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medtronic Stock vs. The Competition

TypeMedtronicMedical CompaniesS&P 500
Consensus Rating Score
2.59
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside3.83% Upside1,097.86% Upside170.76% Upside
News Sentiment Rating
Positive News

See Recent MDT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B-)
10/7/2025Citigroup
3 of 5 stars
Joanne Wuensch
Joanne Wuensch
4 of 5 stars
Boost TargetBuy$101.00 ➝ $112.00+14.03%
10/1/2025The Goldman Sachs Group
3 of 5 stars
 Lower TargetSell$82.00 ➝ $81.00-17.03%
9/12/2025Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$101.00 ➝ $104.00+9.41%
8/26/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$105.00 ➝ $115.00+24.94%
8/21/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$92.00 ➝ $96.00+4.50%
8/20/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$94.00 ➝ $95.00+1.83%
8/20/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$98.00 ➝ $100.00+7.19%
8/20/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$97.00 ➝ $98.00+8.99%
8/20/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$94.00 ➝ $96.00+6.77%
8/14/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/16/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$98.00 ➝ $100.00+12.04%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$98.00 ➝ $107.00+20.16%
7/11/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral
7/11/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$103.00 ➝ $106.00+20.83%
6/30/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperformPeer Perform
6/16/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$110.00+26.16%
5/22/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$105.00 ➝ $101.00+24.10%
11/26/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$105.00 ➝ $109.00+27.11%
11/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$99.00 ➝ $96.00+9.84%
8/23/2024Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetNeutral$85.00 ➝ $90.00+4.41%
8/21/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetHold$85.00 ➝ $87.00+1.90%
8/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetMarket Perform$92.00 ➝ $94.00+10.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:58 AM ET.


Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 8, 2025. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Medtronic plc:

  • The current stock price is around $99, which is close to its 12-month high, indicating strong market performance and investor confidence.
  • Medtronic plc reported a quarterly earnings per share of $1.26, surpassing analysts' expectations, which reflects the company's robust financial health and operational efficiency.
  • The company has shown a year-over-year revenue growth of 7.7%, suggesting a positive trend in sales and demand for its medical technologies.
  • Medtronic plc has a solid dividend yield of 2.9%, providing investors with a reliable income stream, which is particularly attractive in a low-interest-rate environment.
  • Analysts have a generally positive outlook on the stock, with an average rating of "Moderate Buy" and a price target of approximately $100.94, indicating potential for further appreciation.

Medtronic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Medtronic plc for these reasons:

  • The payout ratio is currently at 78.24%, which may indicate that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth opportunities.
  • Despite positive earnings, the stock has not significantly outperformed the market, which may suggest limited upside potential in the near term.
  • Market analysts have mixed ratings, with some holding a "Sell" rating, indicating that not all experts are confident in the stock's future performance.
  • Medtronic plc operates in a highly competitive medical technology sector, which could impact its market share and profitability if competitors introduce superior products.
  • Economic uncertainties and regulatory changes in the healthcare industry could pose risks to Medtronic plc's operations and financial performance.

MDT Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $101.63, with a high forecast of $115.00 and a low forecast of $81.00.

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There is currently 1 sell rating, 8 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 3.83% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 1 upgrade by analysts.

Analysts like Medtronic more than other "medical" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how MDT compares to other companies.


This page (NYSE:MDT) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners